Hematopoietic stem cell transplantation in multiple myeloma

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Novel agents (thalidomide, bortezomib, lenalidomide) are transforming multiple myeloma management.
• These agents are used both in patients eligible for stem cell transplantation and in those not undergoing transplant.

Purpose of the Study:

• To review the impact of novel agents on multiple myeloma treatment, particularly in the context of stem cell transplantation.
• To compare the efficacy of novel agent-based regimens with traditional treatments and evaluate their role before and after transplantation.

Main Methods:

• Review of clinical data and outcomes from studies involving novel agents in multiple myeloma.
• Comparison of response rates, progression-free survival, and overall survival between different treatment regimens and transplant strategies.

Main Results:

• Bortezomib-dexamethasone induction before autologous stem cell transplantation (ASCT) is superior to older regimens.
• Triple combinations including thalidomide and bortezomib show high response rates.
• Thalidomide maintenance post-ASCT improves survival, though optimal dosing is unknown.
• Novel agents achieve excellent results even without transplantation, prompting trials comparing both approaches.
• Tandem ASCT with reduced-intensity conditioning is replacing myeloablative conditioning but carries risks.

Conclusions:

• Novel agents significantly enhance treatment efficacy for multiple myeloma patients undergoing ASCT.
• The role of early transplantation versus novel agents alone requires further investigation through randomized trials.
• While improved, allogeneic transplantation still poses risks and is not recommended for front-line therapy in all patients.